MS Drug Cuts Relapse by 36 %

Wednesday, 20 Mar 2013 12:07 PM

 

Share:
A    A   |
   Email Us   |
   Print   |
   Forward Article  |
  Copy Shortlink
Biogen Idec Inc said on Wednesday its experimental multiple sclerosis drug peginterferon beta-1a reduced the annual relapse rate of patients with multiple sclerosis by 36 percent when dosed once every two weeks.
 
The company, which presented its results at the American Academy of Neurology's annual meeting, said the drug reduced the proportion of patients who relapsed by 39 percent compared with patients who took a placebo.
 
Peginterferon beta-1a, which will be marketed, if approved, under the brand name Plegridy, is an injectable drug designed to reduce the dosing schedule of standard interferon drugs such as Biogen's own Avonex, which are typically dosed at least once a week.
 
In addition to Avonex, Biogen makes the MS drug Tysabri, which is widely considered the most effective on the market but has been linked with a potentially deadly brain infection known as PML.
 
The company is also poised to launch a new MS drug, Tecfidera, a pill that many analysts believe could become the leading treatment for the disease.
 
The company hopes that Plegridy will provide an option for patients seeking a less frequent dosing schedule.
 
Biogen said the drug reduced the risk of 12-week disability progression by 38 percent compared with a placebo when given once every two weeks.
 
When given once every four weeks, Plegridy was also shown to be effective and met the main goals of the trial, but patients who received the drug once every two weeks responded better.
 
Multiple sclerosis is a chronic condition that occurs when the body's immune system mistakenly attacks and destroys the protective sheath surrounding nerve cells in the brain, optic nerve or spinal cord. Symptoms may include loss of balance, difficulty moving arms and legs, weakness, numbness and blindness.
 
Analysts expect the market for interferons to shrink over the next decade as newer generation products, especially pills such as Tecfidera.

© 2014 Thomson/Reuters. All rights reserved.

Share:
   Email Us   |
   Print   |
   Forward Article  |
  Copy Shortlink
Around the Web
Comments
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
 
Find Your Condition
You May Also Like
Around the Web

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

NEWSMAXHEALTH.COM
© Newsmax Media, Inc.
All Rights Reserved